Healthcare Costs Amongst Patients with Non-Small Cell lung cancer (NSCLC) Before and After Testing with a Host Immune Classifier (HIC)

被引：0
|
作者：
Iams, Wade [1 ]
Le, Kimberly [2 ]
Princic, Nicole [3 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Biodesix Inc, Boulder, CO USA
[3] Merative, Ann Arbor, MI USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP01.15
引用
收藏
页码：E14 / E14
页数：1
相关论文
共 50 条
  • [31] HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS RECEIVING ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS
    Lin, C. W.
    To, T. M.
    Ng, C.
    Gupta, R.
    Ogale, S.
    VALUE IN HEALTH, 2021, 24 : S32 - S32
  • [32] Clinical outcomes of patients with non-small cell lung cancer (NSCLC) receiving chemotherapy after immune checkpoint blockade.
    Grigg, Claud
    Reuland, Brian D.
    Sacher, Adrian G.
    Yeh, Randy
    Rizvi, Naiyer A.
    Shu, Catherine A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Pleural lavage cytology before and after lung resection in non-small cell lung cancer patients
    Enatsu, S
    Yoshida, J
    Yokose, T
    Nishimura, M
    Nishiwaki, Y
    Shirakusa, T
    Nagai, K
    ANNALS OF THORACIC SURGERY, 2006, 81 (01): : 298 - 304
  • [34] Genomic and immune characteristics of EGFR subtypes in non-small cell lung cancer (NSCLC)
    Bodor, J. Nicholas
    Xiu, Joanne
    Ernani, Vinicius
    Kaur, Supreet
    Mamdani, Hirva
    Brodskiy, Pavel
    Ou, Sai-Hong I.
    Ma, Patrick C.
    Clapper, Margie L.
    Korn, W. Michael
    Treat, Joseph
    CANCER RESEARCH, 2022, 82 (12)
  • [35] Compliance with oral topotecan in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
    Eckardt, J. R.
    Ramlau, R.
    Gervais, R.
    Shepherd, F.
    O'Brien, M.
    Ciuleanu, T.
    Dharan, B.
    Wissel, P.
    Ross, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 387S - 387S
  • [36] Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC)
    Cramer-van der Welle, Christine
    Peters, Bas J. M.
    Deenen, Maarten J.
    Schramel, Franz M. N. H.
    Van de Garde, Ewoudt M. W.
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [37] VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
    Carbone, David P.
    Salmon, J. Stuart
    Billheimer, Dean
    Chen, Heidi
    Sandler, Alan
    Roder, Heinrich
    Roder, Joanna
    Tsypin, Maxim
    Herbst, Roy S.
    Tsao, Anne S.
    Tran, Hai T.
    Dang, Thao P.
    LUNG CANCER, 2010, 69 (03) : 337 - 340
  • [38] Costs of non-small cell lung cancer in the Netherlands
    van der Linden, N.
    Bongers, M. L.
    Coupe, V. M. H.
    Smit, E. F.
    Groen, H. J. M.
    Welling, A.
    Schramel, F. M. N. H.
    Uyl-de Groot, C. A.
    LUNG CANCER, 2016, 91 : 79 - 88
  • [39] EVALUATION OF BIOMARKERS IN PATIENTS WITH NON-SMALL CELL LUNG-CANCER (NSCLC)
    FOEMMEL, RS
    ALEXANDER, NA
    HIRSHAUT, Y
    KATOPODIS, N
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 : 182 - 182
  • [40] Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
    Papachristos, A.
    Masinde, S.
    Davis, J. D.
    Gullo, G.
    Rietschel, P.
    Paccaly, A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S308 - S309
12345